Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) has been rated by 12 financial analysts over the past three months, with sentiments ranging from bullish to bearish. The average 12-month price target is $148.92, up 32.26% from the previous $112.60, with a high estimate of $224.00 and a low of $80.00. Analysts have maintained, raised, or lowered their ratings and price targets in response to market conditions and company performance. Sarepta is a biotech company focusing on rare diseases, with a recent revenue growth of 44.1% but with a net margin of -12.34% and an ROE of -5.44%. The company's debt-to-equity ratio is 1.79, higher than the industry average.
January 30, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics has received varied analyst ratings, with an updated average price target of $148.92, indicating a positive sentiment. The company's strong revenue growth is a positive sign, but financial challenges such as a high debt-to-equity ratio may concern investors.
The increase in the average price target suggests a positive outlook from analysts, which could lead to a short-term positive impact on SRPT's stock price. However, the company's financial challenges, such as a high debt-to-equity ratio and below-average ROE, may temper investor enthusiasm, hence the importance score is not at the maximum.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100